AHA Journal: Stroke: A Journal of Cerebral Circulation: Published on June, 2022
Millions of women worldwide use
exogenous hormones as oral contraceptives or hormone replacement therapy.
Still, time-dependent and long-term consequences of exogenous hormones on
stroke risk remains unclear.
TAKE-HOME MESSAGE
In this UK Biobank analysis
including 257,194 women, a substantially higher stroke event rate was observed
in women during the first year of oral contraceptive use compared with
nonusers, but the risks were comparable thereafter.
Hormone replacement therapy was
also associated with higher risks of any stroke and cause-specific stroke
within the first year, with persistently higher risks of any stroke after the
first year of use and after discontinuation.
These data show that both oral
contraceptive use and hormone replacement therapy are associated with a
substantially increased risk of stroke, with the risk primarily being evident
during the first year.
Conclusions:
Oral contraceptive use and hormone replacement therapy were associated
with an increased risk of stroke, especially during the first year of use,
possibly due to immediate changes in hemostatic balance.
This study provides new insights on the effects of hormone exposure on stroke risk and provides evidence of not only an overall risk but also pronounced effects seen in the beginning of treatment.
Background:
Millions of women worldwide use exogenous
hormones as oral contraceptives or hormone replacement therapy. Still,
time-dependent and long-term consequences of exogenous hormones on stroke risk
remains unclear.
Methods:
We examined the association between
self-reported oral contraceptive and hormone replacement therapy use and stroke
risk in 257 194 women from the UK Biobank, born between 1939 and 1970. Outcomes
included any type of stroke, ischemic stroke, intracerebral hemorrhage, and
subarachnoid hemorrhage. Exposures were analyzed as time-varying variables in
Cox regression models.
Results:
During first year of oral
contraceptive use, an increased event rate of any stroke was observed, while
the hazards were found to be comparable during remaining years of use, compared
with nonusers. Similarly, first year of hormone replacement therapy use was
associated with higher hazard rates of any stroke, as well as cause-specific
stroke, including ischemic stroke and subarachnoid hemorrhage, which remained
increased for any stroke during remaining years of use, and after
discontinuation.
Conclusions:
Oral contraceptive use and hormone
replacement therapy were associated with an increased risk of stroke,
especially during the first year of use, possibly due to immediate changes in
hemostatic balance. This study provides new insights on the effects of hormone
exposure on stroke risk and provide evidence of not only an overall risk but
also a pronounced effects seen in the beginning of treatment.
Comments
You must login to write comment